Multimodal response to levodopa treatment in advanced and late Parkinson’s disease

Detalhes bibliográficos
Autor(a) principal: Fabbri, Margherita
Data de Publicação: 2018
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/48449
Resumo: Parkinson’s disease (PD) is a progressive age-dependent neurodegenerative disease. Life expectancy increasing and a better knowledge in PD treatment management, including the advent of device-aided therapies, are likely to increase the number of patients who can reach an advanced disease stage and eventually enter the late stage (LS) of the disease in the next decades. LSPD is a recently recognized disease stage, in which patients are severely disable and dependent on activities of daily life (ADLs) due to the presence of poor treatment responsive motor and non-motor symptoms (NMS) thus highly impacting caregiver’s burden and social/health care system. Hence an operational clinical criteria to identify LSPD patients has been recently proposed suggesting adopt a Schwab and England activity of daily life score (S&E) < 50 in the MED ON condition. LSPD patients’ treatment management is challenging. Treatment-related adverse effects (AEs) are frequent and few evidence in terms of phamacological and non-pharmacological treatment efficacy are available as they are barely included in clinical or research studies and even the participation into routine hospital-based visits can be an unsurmountable limit. At the same time, even if general PD disease severity milestones have been described, we do not know how LSPD patients specifically progress, if they do evolve and if there are clinical markers or biomarkers of poor outcome that could be useful to focus specific therapeutic interventions for this specific disease stage. We aimed to deeply characterize the clinical phenotype, needs along with clinical markers or biomarkers of poor outcome of LSPD patients. As levodopa (L-dopa) is the mainstay of PD treatment and a simplification of treatment regimen in later disease stages has been suggested, we also aimed to investigate the real effect of L-dopa on motor symptoms and NMS among LSPD patients, if compared to advanced stage patients. Among NMS, we focused our work particularly on speech impairment, exploring speech response to L-dopa among LSPD patients and to fine stimulation parameters adjustment, in combination with L-dopa, in advanced PD patients submitted to deep brain stimulation (DBS). Participants were LSPD (Schwab and England ADL Scale [S&E] <50 or Hoehn Yahr Stage [HY] >3 in “MED ON” state) and advanced stage PD patients previously submitted to DBS. Cross-sectional data were obtained by means of a comprehensive clinical assessment including a L-dopa challenge test with a suprathreshold dose. A subgroup of thirteen LSPD patients underwent a neuroimaging study in order to study neuromelanin (NM) substantia nigra (SN) area changes in the latest disease stage if compared to previous ones. Automated analysis of speech were used to study the effect of a supramaximal L-dopa dose in twenty-four LSPD patients as well as L-dopa and frequency stimulation adjustment in twenty deep brain stimulated patients. Longitudinal data were collected only for LSPD patients. Descriptive, regression and survival curves analysis were performed. Fifty LSPD patients (female 46%) were included. Mean age was 77.5 ± 5.9 years and mean disease duration was 15.5± 6.5 years. At baseline, 76% had L-dopa-induced motor complications (MCs), mainly non-troublesome, 68%were demented, 54% had psychosis and 68% depression. Caregiver distress was high. L-dopa responsiveness was mild (18% ± 12 of improvement on MDS-UPDRS-III) and present only for appendicular signs, being tremor and rigidity the most responsive ones, while axial signs did not change. The clinical significance of this better motor response was marginal according to the Clinical Global Improvement Scale and the change in the S&E between OFF and ON state. The magnitude of L-dopa response correlated with the acute appearance of dyskinesias and the severity of MCs. After one-year, 20% of the patients were dead, 18% institutionalized in nursing home and 6% passed to a HY 5. MDS-UPDRS-motor mean score worsened 7.2 ± 10.3 points, corresponding to a 15.7% (±23.0) increase, with no difference between tremor-dominant versus akinetic-rigid phenotype or PD patients with/without dementia (PDD/non-PDD) at baseline. However, there was heterogeneity between patients in terms of disease progression, as 12 patients (37.5%) had a motor deterioration ≤ 3 points and 14 (43%) ≤ 5 points with concomitant worsening of the MDS-UPDRS-II (Motor Aspects of Experiences of Daily Living), of 2.1±4.1. Conversely, eleven cases (32%) did not deteriorate and, in fact, 10 of these improved between 1-6 points at the MDS-UPDRS-III. Overall NMS worsened, mostly in cognition/mood, urinary and gastrointestinal domains. Conversely, MCs improved despite similar L-dopa equivalent dose. Functional independence and quality of life worsened. Dysphagia severity at baseline predicted a poor combined outcome (death, being institutionalized or developing HY 5) (Hazard ratio 2.3, 95% CI 1.12- 4.4; p = 0.01) or death alone (Hazard ratio of 2.9, 95% CI 1.12- 8.6, p=0.04), whereas magnitude of L-dopa response of LSPD patients did not. SN area evaluated by NM-sensitive magnetic resonance imaging (MRI), resulted able to differentiate LSPD patients from both de novo PD patients and controls, though not founding statistical differences between LSPD patients and patients with two-five year disease duration. Performing an indirect comparison of the effect of L-dopa on motor symptoms and NMS among twenty LSPD patients and twenty-two, not-matched, advanced PD patients, a milder response on motor symptoms (11% vs. 37% of improvement on MDS-UPDRS-III) and an absence of response on NMS, namely anxiety, fatigue and pain, were found among LSPD patients, with concomitant higher frequency of drug-related AEs. Indeed orthostatic hypotension (OH) or drowsiness occurred among 35% of LSPD patients versus 13% of advanced PD patients, who still presented a benefit from L-dopa intake on pain and anxiety, while fatigue did not change. Scales applicability and blood pressure assessment while standing resulted challenging among LSPD patients with consequent missing data on depression, anxiety, pain and OH identification and possible underestimation of those symptoms. No effect of L-dopa was found on speech and voice by means of both automated analysis and clinical evaluation in LSPD patients. Respiratory support for speech and voice stability were the most affected speech and voice features among LSPD patients. Among axial symptoms, speech seemed to be the most L-dopa unresponsive one. Speech unresponsiveness to L-dopa was confirmed also among subthalamic (STN)-DBS treated patients with both mild and severe dysarthria, at least in combination with stimulation. Conversely, PD patients with severe dysarthria under chronic STN-DBS treatment showed a benefit of lowering frequency of stimulation from 130 Hz (High frequency stimulation [HFS]) to 60Hz (low frequency stimulation [LFS]), with concomitant increment of voltage, in order to keep constant the total energy delivered. Indeed speech intelligibility and articulatory diadochokinesis presented an acute improvement passing from HFS to LFS, as assessed by automated speech analysis and such a benefit, when present and clinically meaningful, lasted during six months with no motor worsening, though requiring medication adjustment. The present study provides further evidence to better delineate a recently recognized and poorly described PD stage. An extensive cross-sectional and longitudinal observation is proposed. LSPD patients clearly differ from previous stages in terms of both clinical features, needs, therapeutic response and drugs’ tolerability profile. Over one year, a heterogeneous disease progression of motor symptoms is still present and it seems even steeper if compared to previous stages, while functional independence globally worsened. As well as mild motor improvements are still possible with treatment adjustment, it is also possible to identify a clinical phenotype of LSPD patients who are likely to have a better response to L-dopa if compared to the other ones. Clinical assessment and therapeutic interventions for swallowing problems should be a priority. PDD or living in a nursing home remain other indicators of poor outcome. In the next few years the number of LSPD patients who have been previously submitted to device-aided therapies is expected to increase, bringing new clinical scenarios, such as the fine parameters adjustment of invasive treatment for challenging motor and NMS and the difficult management or eventual interruption of those treatments among elderly and frail LSPD patients. Overall, future research and fund allocations should be specifically oriented on LSPD patients, usually not included or considered in clinical trials or research studies, and on L-dopa not-responsive aspects and caregivers’ needs
id RCAP_7d0640666daabf8bd5498ff787659119
oai_identifier_str oai:repositorio.ul.pt:10451/48449
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Multimodal response to levodopa treatment in advanced and late Parkinson’s diseaseParkinson’s diseaseLate-stageAdvanced stageLevodopaDisease progressionTeses de doutoramento – 2019Domínio/Área Científica::Ciências Médicas::Medicina ClínicaParkinson’s disease (PD) is a progressive age-dependent neurodegenerative disease. Life expectancy increasing and a better knowledge in PD treatment management, including the advent of device-aided therapies, are likely to increase the number of patients who can reach an advanced disease stage and eventually enter the late stage (LS) of the disease in the next decades. LSPD is a recently recognized disease stage, in which patients are severely disable and dependent on activities of daily life (ADLs) due to the presence of poor treatment responsive motor and non-motor symptoms (NMS) thus highly impacting caregiver’s burden and social/health care system. Hence an operational clinical criteria to identify LSPD patients has been recently proposed suggesting adopt a Schwab and England activity of daily life score (S&E) < 50 in the MED ON condition. LSPD patients’ treatment management is challenging. Treatment-related adverse effects (AEs) are frequent and few evidence in terms of phamacological and non-pharmacological treatment efficacy are available as they are barely included in clinical or research studies and even the participation into routine hospital-based visits can be an unsurmountable limit. At the same time, even if general PD disease severity milestones have been described, we do not know how LSPD patients specifically progress, if they do evolve and if there are clinical markers or biomarkers of poor outcome that could be useful to focus specific therapeutic interventions for this specific disease stage. We aimed to deeply characterize the clinical phenotype, needs along with clinical markers or biomarkers of poor outcome of LSPD patients. As levodopa (L-dopa) is the mainstay of PD treatment and a simplification of treatment regimen in later disease stages has been suggested, we also aimed to investigate the real effect of L-dopa on motor symptoms and NMS among LSPD patients, if compared to advanced stage patients. Among NMS, we focused our work particularly on speech impairment, exploring speech response to L-dopa among LSPD patients and to fine stimulation parameters adjustment, in combination with L-dopa, in advanced PD patients submitted to deep brain stimulation (DBS). Participants were LSPD (Schwab and England ADL Scale [S&E] <50 or Hoehn Yahr Stage [HY] >3 in “MED ON” state) and advanced stage PD patients previously submitted to DBS. Cross-sectional data were obtained by means of a comprehensive clinical assessment including a L-dopa challenge test with a suprathreshold dose. A subgroup of thirteen LSPD patients underwent a neuroimaging study in order to study neuromelanin (NM) substantia nigra (SN) area changes in the latest disease stage if compared to previous ones. Automated analysis of speech were used to study the effect of a supramaximal L-dopa dose in twenty-four LSPD patients as well as L-dopa and frequency stimulation adjustment in twenty deep brain stimulated patients. Longitudinal data were collected only for LSPD patients. Descriptive, regression and survival curves analysis were performed. Fifty LSPD patients (female 46%) were included. Mean age was 77.5 ± 5.9 years and mean disease duration was 15.5± 6.5 years. At baseline, 76% had L-dopa-induced motor complications (MCs), mainly non-troublesome, 68%were demented, 54% had psychosis and 68% depression. Caregiver distress was high. L-dopa responsiveness was mild (18% ± 12 of improvement on MDS-UPDRS-III) and present only for appendicular signs, being tremor and rigidity the most responsive ones, while axial signs did not change. The clinical significance of this better motor response was marginal according to the Clinical Global Improvement Scale and the change in the S&E between OFF and ON state. The magnitude of L-dopa response correlated with the acute appearance of dyskinesias and the severity of MCs. After one-year, 20% of the patients were dead, 18% institutionalized in nursing home and 6% passed to a HY 5. MDS-UPDRS-motor mean score worsened 7.2 ± 10.3 points, corresponding to a 15.7% (±23.0) increase, with no difference between tremor-dominant versus akinetic-rigid phenotype or PD patients with/without dementia (PDD/non-PDD) at baseline. However, there was heterogeneity between patients in terms of disease progression, as 12 patients (37.5%) had a motor deterioration ≤ 3 points and 14 (43%) ≤ 5 points with concomitant worsening of the MDS-UPDRS-II (Motor Aspects of Experiences of Daily Living), of 2.1±4.1. Conversely, eleven cases (32%) did not deteriorate and, in fact, 10 of these improved between 1-6 points at the MDS-UPDRS-III. Overall NMS worsened, mostly in cognition/mood, urinary and gastrointestinal domains. Conversely, MCs improved despite similar L-dopa equivalent dose. Functional independence and quality of life worsened. Dysphagia severity at baseline predicted a poor combined outcome (death, being institutionalized or developing HY 5) (Hazard ratio 2.3, 95% CI 1.12- 4.4; p = 0.01) or death alone (Hazard ratio of 2.9, 95% CI 1.12- 8.6, p=0.04), whereas magnitude of L-dopa response of LSPD patients did not. SN area evaluated by NM-sensitive magnetic resonance imaging (MRI), resulted able to differentiate LSPD patients from both de novo PD patients and controls, though not founding statistical differences between LSPD patients and patients with two-five year disease duration. Performing an indirect comparison of the effect of L-dopa on motor symptoms and NMS among twenty LSPD patients and twenty-two, not-matched, advanced PD patients, a milder response on motor symptoms (11% vs. 37% of improvement on MDS-UPDRS-III) and an absence of response on NMS, namely anxiety, fatigue and pain, were found among LSPD patients, with concomitant higher frequency of drug-related AEs. Indeed orthostatic hypotension (OH) or drowsiness occurred among 35% of LSPD patients versus 13% of advanced PD patients, who still presented a benefit from L-dopa intake on pain and anxiety, while fatigue did not change. Scales applicability and blood pressure assessment while standing resulted challenging among LSPD patients with consequent missing data on depression, anxiety, pain and OH identification and possible underestimation of those symptoms. No effect of L-dopa was found on speech and voice by means of both automated analysis and clinical evaluation in LSPD patients. Respiratory support for speech and voice stability were the most affected speech and voice features among LSPD patients. Among axial symptoms, speech seemed to be the most L-dopa unresponsive one. Speech unresponsiveness to L-dopa was confirmed also among subthalamic (STN)-DBS treated patients with both mild and severe dysarthria, at least in combination with stimulation. Conversely, PD patients with severe dysarthria under chronic STN-DBS treatment showed a benefit of lowering frequency of stimulation from 130 Hz (High frequency stimulation [HFS]) to 60Hz (low frequency stimulation [LFS]), with concomitant increment of voltage, in order to keep constant the total energy delivered. Indeed speech intelligibility and articulatory diadochokinesis presented an acute improvement passing from HFS to LFS, as assessed by automated speech analysis and such a benefit, when present and clinically meaningful, lasted during six months with no motor worsening, though requiring medication adjustment. The present study provides further evidence to better delineate a recently recognized and poorly described PD stage. An extensive cross-sectional and longitudinal observation is proposed. LSPD patients clearly differ from previous stages in terms of both clinical features, needs, therapeutic response and drugs’ tolerability profile. Over one year, a heterogeneous disease progression of motor symptoms is still present and it seems even steeper if compared to previous stages, while functional independence globally worsened. As well as mild motor improvements are still possible with treatment adjustment, it is also possible to identify a clinical phenotype of LSPD patients who are likely to have a better response to L-dopa if compared to the other ones. Clinical assessment and therapeutic interventions for swallowing problems should be a priority. PDD or living in a nursing home remain other indicators of poor outcome. In the next few years the number of LSPD patients who have been previously submitted to device-aided therapies is expected to increase, bringing new clinical scenarios, such as the fine parameters adjustment of invasive treatment for challenging motor and NMS and the difficult management or eventual interruption of those treatments among elderly and frail LSPD patients. Overall, future research and fund allocations should be specifically oriented on LSPD patients, usually not included or considered in clinical trials or research studies, and on L-dopa not-responsive aspects and caregivers’ needsFerreira, Joaquim José CoutinhoAntonini, AngeloRepositório da Universidade de LisboaFabbri, Margherita2021-06-09T17:05:12Z2019-052018-112019-05-01T00:00:00Zdoctoral thesisinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10451/48449TID:101518927enginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-11-20T18:06:10Zoai:repositorio.ul.pt:10451/48449Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-11-20T18:06:10Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Multimodal response to levodopa treatment in advanced and late Parkinson’s disease
title Multimodal response to levodopa treatment in advanced and late Parkinson’s disease
spellingShingle Multimodal response to levodopa treatment in advanced and late Parkinson’s disease
Fabbri, Margherita
Parkinson’s disease
Late-stage
Advanced stage
Levodopa
Disease progression
Teses de doutoramento – 2019
Domínio/Área Científica::Ciências Médicas::Medicina Clínica
title_short Multimodal response to levodopa treatment in advanced and late Parkinson’s disease
title_full Multimodal response to levodopa treatment in advanced and late Parkinson’s disease
title_fullStr Multimodal response to levodopa treatment in advanced and late Parkinson’s disease
title_full_unstemmed Multimodal response to levodopa treatment in advanced and late Parkinson’s disease
title_sort Multimodal response to levodopa treatment in advanced and late Parkinson’s disease
author Fabbri, Margherita
author_facet Fabbri, Margherita
author_role author
dc.contributor.none.fl_str_mv Ferreira, Joaquim José Coutinho
Antonini, Angelo
Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Fabbri, Margherita
dc.subject.por.fl_str_mv Parkinson’s disease
Late-stage
Advanced stage
Levodopa
Disease progression
Teses de doutoramento – 2019
Domínio/Área Científica::Ciências Médicas::Medicina Clínica
topic Parkinson’s disease
Late-stage
Advanced stage
Levodopa
Disease progression
Teses de doutoramento – 2019
Domínio/Área Científica::Ciências Médicas::Medicina Clínica
description Parkinson’s disease (PD) is a progressive age-dependent neurodegenerative disease. Life expectancy increasing and a better knowledge in PD treatment management, including the advent of device-aided therapies, are likely to increase the number of patients who can reach an advanced disease stage and eventually enter the late stage (LS) of the disease in the next decades. LSPD is a recently recognized disease stage, in which patients are severely disable and dependent on activities of daily life (ADLs) due to the presence of poor treatment responsive motor and non-motor symptoms (NMS) thus highly impacting caregiver’s burden and social/health care system. Hence an operational clinical criteria to identify LSPD patients has been recently proposed suggesting adopt a Schwab and England activity of daily life score (S&E) < 50 in the MED ON condition. LSPD patients’ treatment management is challenging. Treatment-related adverse effects (AEs) are frequent and few evidence in terms of phamacological and non-pharmacological treatment efficacy are available as they are barely included in clinical or research studies and even the participation into routine hospital-based visits can be an unsurmountable limit. At the same time, even if general PD disease severity milestones have been described, we do not know how LSPD patients specifically progress, if they do evolve and if there are clinical markers or biomarkers of poor outcome that could be useful to focus specific therapeutic interventions for this specific disease stage. We aimed to deeply characterize the clinical phenotype, needs along with clinical markers or biomarkers of poor outcome of LSPD patients. As levodopa (L-dopa) is the mainstay of PD treatment and a simplification of treatment regimen in later disease stages has been suggested, we also aimed to investigate the real effect of L-dopa on motor symptoms and NMS among LSPD patients, if compared to advanced stage patients. Among NMS, we focused our work particularly on speech impairment, exploring speech response to L-dopa among LSPD patients and to fine stimulation parameters adjustment, in combination with L-dopa, in advanced PD patients submitted to deep brain stimulation (DBS). Participants were LSPD (Schwab and England ADL Scale [S&E] <50 or Hoehn Yahr Stage [HY] >3 in “MED ON” state) and advanced stage PD patients previously submitted to DBS. Cross-sectional data were obtained by means of a comprehensive clinical assessment including a L-dopa challenge test with a suprathreshold dose. A subgroup of thirteen LSPD patients underwent a neuroimaging study in order to study neuromelanin (NM) substantia nigra (SN) area changes in the latest disease stage if compared to previous ones. Automated analysis of speech were used to study the effect of a supramaximal L-dopa dose in twenty-four LSPD patients as well as L-dopa and frequency stimulation adjustment in twenty deep brain stimulated patients. Longitudinal data were collected only for LSPD patients. Descriptive, regression and survival curves analysis were performed. Fifty LSPD patients (female 46%) were included. Mean age was 77.5 ± 5.9 years and mean disease duration was 15.5± 6.5 years. At baseline, 76% had L-dopa-induced motor complications (MCs), mainly non-troublesome, 68%were demented, 54% had psychosis and 68% depression. Caregiver distress was high. L-dopa responsiveness was mild (18% ± 12 of improvement on MDS-UPDRS-III) and present only for appendicular signs, being tremor and rigidity the most responsive ones, while axial signs did not change. The clinical significance of this better motor response was marginal according to the Clinical Global Improvement Scale and the change in the S&E between OFF and ON state. The magnitude of L-dopa response correlated with the acute appearance of dyskinesias and the severity of MCs. After one-year, 20% of the patients were dead, 18% institutionalized in nursing home and 6% passed to a HY 5. MDS-UPDRS-motor mean score worsened 7.2 ± 10.3 points, corresponding to a 15.7% (±23.0) increase, with no difference between tremor-dominant versus akinetic-rigid phenotype or PD patients with/without dementia (PDD/non-PDD) at baseline. However, there was heterogeneity between patients in terms of disease progression, as 12 patients (37.5%) had a motor deterioration ≤ 3 points and 14 (43%) ≤ 5 points with concomitant worsening of the MDS-UPDRS-II (Motor Aspects of Experiences of Daily Living), of 2.1±4.1. Conversely, eleven cases (32%) did not deteriorate and, in fact, 10 of these improved between 1-6 points at the MDS-UPDRS-III. Overall NMS worsened, mostly in cognition/mood, urinary and gastrointestinal domains. Conversely, MCs improved despite similar L-dopa equivalent dose. Functional independence and quality of life worsened. Dysphagia severity at baseline predicted a poor combined outcome (death, being institutionalized or developing HY 5) (Hazard ratio 2.3, 95% CI 1.12- 4.4; p = 0.01) or death alone (Hazard ratio of 2.9, 95% CI 1.12- 8.6, p=0.04), whereas magnitude of L-dopa response of LSPD patients did not. SN area evaluated by NM-sensitive magnetic resonance imaging (MRI), resulted able to differentiate LSPD patients from both de novo PD patients and controls, though not founding statistical differences between LSPD patients and patients with two-five year disease duration. Performing an indirect comparison of the effect of L-dopa on motor symptoms and NMS among twenty LSPD patients and twenty-two, not-matched, advanced PD patients, a milder response on motor symptoms (11% vs. 37% of improvement on MDS-UPDRS-III) and an absence of response on NMS, namely anxiety, fatigue and pain, were found among LSPD patients, with concomitant higher frequency of drug-related AEs. Indeed orthostatic hypotension (OH) or drowsiness occurred among 35% of LSPD patients versus 13% of advanced PD patients, who still presented a benefit from L-dopa intake on pain and anxiety, while fatigue did not change. Scales applicability and blood pressure assessment while standing resulted challenging among LSPD patients with consequent missing data on depression, anxiety, pain and OH identification and possible underestimation of those symptoms. No effect of L-dopa was found on speech and voice by means of both automated analysis and clinical evaluation in LSPD patients. Respiratory support for speech and voice stability were the most affected speech and voice features among LSPD patients. Among axial symptoms, speech seemed to be the most L-dopa unresponsive one. Speech unresponsiveness to L-dopa was confirmed also among subthalamic (STN)-DBS treated patients with both mild and severe dysarthria, at least in combination with stimulation. Conversely, PD patients with severe dysarthria under chronic STN-DBS treatment showed a benefit of lowering frequency of stimulation from 130 Hz (High frequency stimulation [HFS]) to 60Hz (low frequency stimulation [LFS]), with concomitant increment of voltage, in order to keep constant the total energy delivered. Indeed speech intelligibility and articulatory diadochokinesis presented an acute improvement passing from HFS to LFS, as assessed by automated speech analysis and such a benefit, when present and clinically meaningful, lasted during six months with no motor worsening, though requiring medication adjustment. The present study provides further evidence to better delineate a recently recognized and poorly described PD stage. An extensive cross-sectional and longitudinal observation is proposed. LSPD patients clearly differ from previous stages in terms of both clinical features, needs, therapeutic response and drugs’ tolerability profile. Over one year, a heterogeneous disease progression of motor symptoms is still present and it seems even steeper if compared to previous stages, while functional independence globally worsened. As well as mild motor improvements are still possible with treatment adjustment, it is also possible to identify a clinical phenotype of LSPD patients who are likely to have a better response to L-dopa if compared to the other ones. Clinical assessment and therapeutic interventions for swallowing problems should be a priority. PDD or living in a nursing home remain other indicators of poor outcome. In the next few years the number of LSPD patients who have been previously submitted to device-aided therapies is expected to increase, bringing new clinical scenarios, such as the fine parameters adjustment of invasive treatment for challenging motor and NMS and the difficult management or eventual interruption of those treatments among elderly and frail LSPD patients. Overall, future research and fund allocations should be specifically oriented on LSPD patients, usually not included or considered in clinical trials or research studies, and on L-dopa not-responsive aspects and caregivers’ needs
publishDate 2018
dc.date.none.fl_str_mv 2018-11
2019-05
2019-05-01T00:00:00Z
2021-06-09T17:05:12Z
dc.type.driver.fl_str_mv doctoral thesis
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/48449
TID:101518927
url http://hdl.handle.net/10451/48449
identifier_str_mv TID:101518927
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817549135225552896